## ON: ON Semiconductor Corporation - XLK: Technology

### Executive Summary

No thesis match: MRS_20 3.6% below STRENGTH zone (4.0-10.0%); PEG 1.75 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: declining volume (54% of avg).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($53.30)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Allspring Global Investments Holdings LLC Purchases 53,748 Shares of ON Semiconductor Corporation $ON**
- Source: MarketBeat | 20251231T084328 | Somewhat-Bullish | Relevance: 100%
- Allspring Global Investments Holdings LLC increased its stake in ON Semiconductor Corporation by 0.9% in Q3, acquiring an additional 53,748 shares, bringing its total holdings to 5,889,080 shares valued at approximately $284.7 million. The semiconductor company recently beat Q3 earnings estimates and provided optimistic Q4 guidance, despite facing some negative sentiment regarding its valuation and underperformance compared to competitors. Institutional investors now own 97.7% of the company, and various analysts have issued "Buy" and "Hold" ratings, with a consensus target price of $59.35.

**2. ON Semiconductor Corporation $ON Shares Sold by Boston Trust Walden Corp**
- Source: MarketBeat | 20251231T085728 | Somewhat-Bullish | Relevance: 100%
- Boston Trust Walden Corp significantly reduced its stake in ON Semiconductor Corporation by 30.5%, selling 76,050 shares and retaining 173,295 shares valued at approximately $8.545 million. Despite this, ON Semiconductor reported strong Q3 earnings, beating estimates and authorizing a substantial $6.0 billion share buyback program. The company faces a mixed analyst outlook with a consensus "Hold" rating, while an executive insider sale was also noted.

**3. Ascendis Pharma encerra janela de exercício de warrants e aumenta capital social**
- Source: Investing.com Brasil - Finanças, Câmbio e Investimentos | 20251231T050915 | Somewhat-Bullish | Relevance: 63%
- Ascendis Pharma A/S announced that the exercise window for its outstanding warrants for ordinary shares has closed. The company registered an aggregate nominal share capital increase of DKK 282,197, resulting in a total nominal share capital of DKK 61,977,408 after the issuance of 282,197 new ordinary shares. The average cash consideration received per share was approximately $63.34.

**4. GlobalFoundries stock rating downgraded to Neutral by Wedbush**
- Source: Investing.com | 20251231T130832 | Somewhat-Bullish | Relevance: 61%
- Wedbush downgraded GlobalFoundries Inc. (NASDAQ:GFS) from Outperform to Neutral and lowered its price target to $40.00 from $42.00, citing an extended timeline for positive catalysts. Despite a long-term positive outlook on the company's business model, Wedbush revised its growth trajectory and near-term prospects, aligning with downward revisions in earnings expectations by six analysts. GlobalFoundries has other recent developments including a collaboration with ON Semiconductor for GaN power devices, securing €495 million in German state aid for a new facility, and a strategic partnership with Navitas Semiconductor.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-19 | Truist Securiti | $57 | $51 | +12% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-19 | Truist Securiti | main | Hold |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.01M) |
| Sells | 2 ($2.27M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 62.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- FMR, LLC: 15.0% (+8.0%)
- Vanguard Group Inc: 12.8% (-0.1%)
- Blackrock Inc.: 10.0% (-8.6%)
- JPMORGAN CHASE & CO: 7.5% (+126.4%)
- State Street Corpora: 4.8% (-1.2%)

### Key Risks

1. Volume divergence: price rising (+3.8% MRS) on declining volume (54% of avg) suggests distribution.
2. High short interest (16.8%, 4.5 days to cover): squeeze risk or crowded bearish bet.
3. Market regime shift could impact high-beta names disproportionately.

### Catalysts

- Momentum building: MRS_20 improving +3.8% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.75 elevated, pricing in significant growth expectations. Forward P/E 19.5x attractive for 25% earnings growth. Balance sheet: strong liquidity (5.2x). Analyst sentiment positive (1 raises, avg +12%). Insider selling cluster ($2.3M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $23.2B |
| Beta | 1.57 |
| 52W Range | $31.04 - $67.00 |
| Short Interest | 16.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.75 |
| Forward P/E | 19.5 |
| Current P/E | 24.3 |
| YoY Growth | 25.0% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -0.2% to 3.6% (+3.8% in 5 days), confirming momentum buildup. Below STRENGTH zone by 0.4pp (needs >4.0% for momentum thesis). MRS_5 at 4.1% confirms short-term momentum alignment. AM_20 at 3.0% shows strong absolute momentum above own 20MA. Outperforming sector by 3.5pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). Volume at 54% of 20MA suggests lack of conviction. OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 3.60% (CS: 84) | Neutral |
| RSI_14 | 61.7 | Neutral |
| MACD Histogram | -0.15 | Bearish |
| vs SMA20 | 1.030x | Above |
| vs SMA50 | 1.098x | Above |
| vs SMA200 | 1.158x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $56.70
- **Stop Loss:** $53.30 (6.0% risk)
- **Target:** $60.10 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 352
- **Position Value:** $19,958.40
- **Portfolio %:** 19.96%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with stable risk appetite as 2026 trading begins. VIX at 14.51 (4th percentile) signals complacency while positive yield curve (+65bps) and moderate breadth (53.1%) support continuation. Focus on upcoming jobs data (Jan 9) and earnings season kickoff mid-January for directional catalysts.*

### Earnings

**Next:** 2026-02-09 (Est: $0.62)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.59 | $0.63 | +6.6% |
| 2025Q2 | $0.53 | $0.53 | -0.4% |
| 2025Q1 | $0.50 | $0.55 | +9.6% |
| 2024Q4 | $0.97 | $0.95 | -2.4% |

---
*RULE-based L3 | 2026-01-06 17:52 | MRS_20*